BPC-157, Thymosin Beta-4 and GHK-Cu in Angiogenesis Research: Endothelial Assays, Vessel Models and Conflicting Findings

RESEARCH · GLOW BLEND · ANGIOGENESIS AND VESSEL MODELS

BPC-157, Thymosin Beta-4 and GHK-Cu in Angiogenesis Research: Endothelial Assays, Vessel Models and Conflicting Findings

PurixLab’s GLOW BLEND 70mg is a research vial combining BPC-157, TB-500 and GHK-Cu. Our earlier articles cover the blend’s components, copper chemistry and blend stability, dermal wound models and cornea and ocular surface models. This article focuses on one shared theme: blood vessel formation. Each molecule has been described as pro-angiogenic, but the assays and mechanisms differ, and several key findings conflict. These are findings from published research on the individual molecules; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

How angiogenesis is measured

Angiogenesis studies use a ladder of models: endothelial cell proliferation, migration and tube formation; tissue explants such as artery rings and the chick chorioallantoic membrane (CAM); and in vivo models such as gel plugs, cornea pockets, ischaemic limbs and wounds. A positive result at one level does not guarantee one at another.

BPC-157: VEGFR2 and nitric oxide

An early rat study separated the two levels clearly. It found no direct angiogenic effect of BPC-157 in cell cultures, yet crushed or transected muscle and tendon from treated animals showed modulated angiogenesis on VEGF, CD34 and FVIII staining, and the authors linked the effect to up-regulated VEGF expression in healing tissue [1].

Later work reported direct endothelial effects. In a 2017 study, BPC-157 increased vessel density in the CAM assay and in endothelial tube formation, accelerated blood flow recovery in the ischaemic rat hind limb, and increased VEGFR2 expression in muscle. In human vascular endothelial cells it raised VEGFR2 mRNA and protein but not VEGF-A, promoted VEGFR2 internalisation, and activated VEGFR2-Akt-eNOS signalling; the endocytosis inhibitor dynasore blocked these effects [2]. The same group later showed endothelium-dependent, nitric-oxide-mediated relaxation of isolated rat aorta, blocked by L-NAME or haemoglobin, and placed Src and caveolin-1 upstream of eNOS activation [3].

  • Human artery rings. Segments of internal mammary artery left over from 12 bypass operations relaxed in a concentration-dependent way, more when the endothelium was intact. L-NAME attenuated the relaxation, but residual effects suggested additional mechanisms [4].
  • A proposed intracellular partner. A 2026 study reported that intracellular BPC-157 binds the ubiquitin ligase adaptor FBXO22 through its proline at position 3, stabilising the transcription factor BACH1 and enhancing endothelial proliferation and tube formation [5].

The contrast between no direct cell effect [1] and clear tube formation [2] has not been resolved, and VEGFR2 and FBXO22 remain candidate mechanisms.

Thymosin beta-4: migration, sprouting and a binding-site conflict

Thymosin beta-4 (Tβ4) entered angiogenesis research through endothelial differentiation. Its mRNA rises about five-fold when human umbilical vein endothelial cells (HUVECs) form capillary-like tubes, and added Tβ4 increased tube formation and roughly doubled vessel area in coronary artery ring sprouting. The authors reported that cell-surface binding did not appear to involve the actin-binding domain [6]. Tβ4 also acted as an endothelial chemoattractant, increasing HUVEC migration four- to sixfold in Boyden chambers, raising matrix metalloproteinase production, and stimulating migration into subcutaneous gel plugs in vivo [7].

A later study reached the opposite conclusion on the binding site. Using natural Tβ4, fragments and synthetic peptides, it found that the seven-amino-acid actin-binding motif was essential: Tβ4 and the motif alone had near-identical activity at about 50 nM, peptides lacking the motif were inactive, and soluble actin inhibited adhesion and sprouting [8]. Another group found that three overlapping Tβ4 fragments, each spanning the central actin-binding region, were pro-angiogenic in vitro and in vivo, with activity modulated by the N-terminus [9]. This matters for GLOW BLEND because TB-500 has been described as a synthetic, N-acetylated version of LKKTETQ, the actin-binding segment of Tβ4, rather than the full protein [10]. If the actin-binding motif carries the activity, as one study found [8], the fragment could retain it; if cell binding occurs elsewhere on the molecule, as another reported [6], it might not.

Proposed mechanisms include stabilisation of HIF-1α protein, which in turn induces VEGF [11], and Notch and NF-κB signalling: in a mouse critical limb ischaemia model, lentiviral Tβ4 overexpression increased CD31, α-SMA, Ang2, Tie2 and VEGFA [12].

The coronary development paradox

A high-profile mouse study using cardiac knockdown identified Tβ4 as essential for all aspects of coronary vessel development, showed that it stimulated outgrowth from adult epicardial explants with differentiation into endothelial and smooth muscle cells, and implicated its cleavage product AcSDKP [13]. Five years later, global and cardiac-specific Tβ4 knockout mice were born at Mendelian ratios with normal heart and blood vessel formation, and adult knockouts had normal capillary density and cardiac function. The authors concluded that Tβ4 is dispensable for heart and coronary vessel development, and noted that shRNA knockdown can have off-target effects [14]. Exogenous Tβ4 can still affect vessels without being required for their development.

GHK-Cu: copper and its carriers

Copper itself is the starting point. In the rabbit cornea, ceruloplasmin, heparin and glycyl-L-histidyl-L-lysine all induced new capillaries, but only when bound to copper [15]. A later study pointed the other way: peptides released by proteolysis of the matrix protein SPARC, containing the sequence KGHK or GHK, stimulated endothelial cord formation and angiogenesis in vivo. KGHK bound copper with high affinity, yet pre-incubation with copper was not required, and the activity appeared sequence-specific and independent of bound copper [16].

  • Growth factors. In human dermal fibroblasts from irradiated tissue, GHK-Cu exposure increased production of basic fibroblast growth factor and VEGF early after treatment [17].
  • Endothelial cells and wounds. GHK-Cu in liposomes increased HUVEC proliferation by 33.1%, raised VEGF and FGF-2 expression, and improved angiogenesis and CD31 staining in a mouse scald model compared with free GHK-Cu [18]. The formulation was part of the result, so it cannot be read as a property of GHK-Cu alone.

Side by side

  • Tβ4: the broadest mechanistic data, from several groups [7,6,11].
  • BPC-157: the most direct vascular tone data, including human artery tissue [3,4].
  • GHK-Cu: the most indirect evidence, much of it about copper, related peptides or delivery systems [15,16,18].

What a blend study would need

We found no published study testing BPC-157, a Tβ4 fragment and GHK-Cu together in any angiogenesis model. A useful design would test each component alone and combined in the same assays, confirm each peptide is intact in the mixture, and include copper-only controls, because copper is itself angiogenic in some models [15].

What remains open

  • Whether TB-500 shares the angiogenic activity of full-length Tβ4.
  • Whether BPC-157 acts directly on endothelial cells or mainly through injured tissue.
  • Whether GHK activity depends on bound copper.

GLOW BLEND 70mg at PurixLab

GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View GLOW BLEND 70mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-6. PubMed 20388964
  2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966 · doi:10.1007/s00109-016-1488-y
  3. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PubMed 33051481 · PMC7555539 · doi:10.1038/s41598-020-74022-y
  4. Yildirim AK, Dastan AO, Demeli Ertus M, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. 2026;15(9):3488. PubMed 42123221 · PMC13163310 · doi:10.3390/jcm15093488
  5. Zhang J, Liu M, Ou H, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Commun Signal. 2026;24(1):149. PubMed 41606641 · PMC12947506 · doi:10.1186/s12964-026-02694-6
  6. Grant DS, Rose W, Yaen C, et al. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-35. PubMed 14517430 · doi:10.1023/a:1009041911493
  7. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-81. PubMed 9194528 · doi:10.1096/fasebj.11.6.9194528
  8. Philp D, Huff T, Gho YS, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-5. PubMed 14500546 · doi:10.1096/fj.03-0121fje
  9. Dettin M, Ghezzo F, Conconi MT, et al. In vitro and in vivo pro-angiogenic effects of thymosin-β4-derived peptides. Cell Immunol. 2011;271(2):299-307. PubMed 21872226 · doi:10.1016/j.cellimm.2011.07.008
  10. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
  11. Jo JO, Kim SR, Bae MK, et al. Thymosin β4 induces the expression of vascular endothelial growth factor (VEGF) in a hypoxia-inducible factor (HIF)-1α-dependent manner. Biochim Biophys Acta. 2010;1803(11):1244-51. PubMed 20691219 · doi:10.1016/j.bbamcr.2010.07.005
  12. Lv S, Cai H, Xu Y, et al. Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway. Int J Mol Med. 2020;46(4):1347-1358. PubMed 32945357 · PMC7447324 · doi:10.3892/ijmm.2020.4701
  13. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-82. PubMed 17108969 · doi:10.1038/nature05383
  14. Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-64. PubMed 22158707 · PMC3739283 · doi:10.1161/CIRCRESAHA.111.258616
  15. Raju KS, Alessandri G, Ziche M, et al. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst. 1982;69(5):1183-8. PubMed 6182332
  16. Lane TF, Iruela-Arispe ML, Johnson RS, et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol. 1994;125(4):929-43. PubMed 7514608 · PMC2120067 · doi:10.1083/jcb.125.4.929
  17. Pollard JD, Quan S, Kang T, et al. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31. PubMed 15655171 · doi:10.1001/archfaci.7.1.27
  18. Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270-278. PubMed 28370978 · doi:10.1111/wrr.12520

Leave a Comment

Your email address will not be published. Required fields are marked *